Number of children relapsing by 12 to 24 months · children with nephrotic syndrome
Steroid therapy in first episode of nephrotic syndrome: 3 months or… may leads to lower number of children relapsing by 12 to 24 months compared with 2 months of therapy (low certainty).
1 finding from 1 review
Number with frequent relapses by 12 to 24 months stratified by risk of selection bias: Low risk of selection bias · children with nephrotic syndrome
Steroid therapy in first episode of nephrotic syndrome: 3 months or… showed no clear difference in number with frequent relapses by 12 to 24 months stratified by risk… compared with 2 months of therapy (high certainty).
1 finding from 1 review
Number with frequent relapses by 12 to 24 months stratified by risk of bias for allocation concealment: unclear or high risk of bias for allocation bias · children with nephrotic syndrome
Steroid therapy in first episode of nephrotic syndrome: 3 months or… may leads to lower number with frequent relapses by 12 to 24 months stratified by risk… compared with 2 months of therapy (low certainty).
1 finding from 1 review
Adverse events: psychological disorders · children with nephrotic syndrome
Steroid therapy in first episode of nephrotic syndrome: 3 months or… showed no clear difference in adverse events: psychological disorders compared with 2 months of therapy (low certainty).
1 finding from 1 review
Adverse events: hypertension · children with nephrotic syndrome
Steroid therapy in first episode of nephrotic syndrome: 3 months or… showed no clear difference in adverse events: hypertension compared with 2 months of therapy (moderate certainty).
1 finding from 1 review
Adverse events: Cushing's syndrome · children with nephrotic syndrome
Steroid therapy in first episode of nephrotic syndrome: 3 months or… showed no clear difference in adverse events: Cushing's syndrome compared with 2 months of therapy (moderate certainty).
1 finding from 1 review
Birth weight equal to or more than 4000 g · childbearing women and their infants (all) (important/secondary outcomes)
1 finding from 1 review
Clinical relapse · Participants with Crohn's disease in remission
Infliximab combined with purine analogues probably leads to lower clinical relapse (at 48 weeks, CDAI of 150 or greater together with… compared with purine analogues (moderate certainty).
1 finding from 1 review
Parent health, functioning, and quality of life Patient‐Reported Outcomes Measurement Information System (PROMIS) (higher scores = more of the outcome of interest, which can mean improvement or deterioration depending on the outcome) · children with medical complexity
1 finding from 1 review
Scar improvement (POSAS) (0–10, higher score = more severe scarring) · people with burn wounds likely to develop hypertrophic scarring
2 findings from 1 review
Pain (POSAS 0–10, higher score = more severe pain, VAS 0–10, higher score = more severe pruritus) · people with burn wounds likely to develop hypertrophic scarring
1 finding from 1 review
Pruritus · people with burn wounds likely to develop hypertrophic scarring
1 finding from 1 review
QoL · people with burn wounds likely to develop hypertrophic scarring
1 finding from 1 review
Scar improvement (POSAS) (0–10, higher score = more severe scarring) · people with burn wounds likely to develop hypertrophic scarring
2 findings from 1 review
Pain (VAS 0–10, higher score = more severe pain) · people with burn wounds likely to develop hypertrophic scarring
1 finding from 1 review
Pruritus · people with burn wounds likely to develop hypertrophic scarring
1 finding from 1 review
Scar improvement (POSAS) (0–10, higher score = more severe scarring) · people with burn wounds likely to develop hypertrophic scarring
2 findings from 1 review
Pain (POSAS 0–10, higher score = more severe pain) · people with burn wounds likely to develop hypertrophic scarring
1 finding from 1 review
Pruritus · people with burn wounds likely to develop hypertrophic scarring
1 finding from 1 review
QoL · people with burn wounds likely to develop hypertrophic scarring
1 finding from 1 review